Abraxis Pharmaceutical News
Most Popular Abraxis Pharmaceutical Story
Celgene strikes $2.9B deal to acquire Abraxis
With an eye to burnishing its oncology rep and its already sizable revenue, Celgene has struck a deal to buy Abraxis BioScience for cash and stock totaling $2.9 billion. The buyout gives Celgene Read more...
Latest Headlines
- November 21, 2011
- June 30, 2010
- November 5, 2009
- January 20, 2009
- September 5, 2008
- June 16, 2008
- August 21, 2007
- July 1, 2007
- April 26, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
